Karin Vanderkeren obtained her PhD in Sciences in 1994 at the Vrije Universiteit Brussel. From 2004 on she became assistant professor and since 2014 full professor at the Vrije Universiteit Brussel. She is leading the research team of Hematology & Immunology and research has been focused on the pathobiology of multiple myeloma with special emphasis on the role of the microenvironment and the processes involved in the occurrence of drug resistance, all with final goal to obtain new therapeutical strategies. For this purpose the syngeneic, murine 5TMM myeloma models were fully developed and characterized, and used in various studies including collaborations with pharma industry.
From October 2016 on, she is also vice-rector research of the Vrije Universiteit Brussel.